Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

BACKGROUND: Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepatocell...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593858/
https://ncbi.nlm.nih.gov/pubmed/30980420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15245
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky